Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy

[Display omitted] Conventional eye drops quickly move away from the surface of the eye; as a result, ocular bioavailability is very limited. To overcome this issue, we developed a thermosensitive hexanoyl glycol chitosan (HGC) as a carrier for topical drug delivery to the eye. Here, we modulated the...

Full description

Saved in:
Bibliographic Details
Published in:Acta biomaterialia 2016-07, Vol.39, p.124-132
Main Authors: Cho, Ik Sung, Park, Chun Gwon, Huh, Beom Kang, Cho, Myeong Ok, Khatun, Zehedina, Li, Zhengzheng, Kang, Sun-Woong, Choy, Young Bin, Huh, Kang Moo
Format: Article
Language:English
Subjects:
Administration, Ophthalmic
Animals
Brimonidine Tartrate - chemistry
Brimonidine Tartrate - pharmacokinetics
Brimonidine Tartrate - pharmacology
Chitosan
Delayed-Action Preparations - chemistry
Delayed-Action Preparations - pharmacokinetics
Delayed-Action Preparations - pharmacology
Drug delivery systems
Eyes
Formulations
Glaucoma
Glaucoma - drug therapy
Glaucoma - metabolism
Glaucoma therapy
Glycols
Glycols - chemistry
Glycols - pharmacokinetics
Glycols - pharmacology
Hexanoyl glycol chitosan
Hot Temperature
Male
Ocular delivery
Rabbits
Thermosensitive
Thermosensitive property
Viscosity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Conventional eye drops quickly move away from the surface of the eye; as a result, ocular bioavailability is very limited. To overcome this issue, we developed a thermosensitive hexanoyl glycol chitosan (HGC) as a carrier for topical drug delivery to the eye. Here, we modulated the degree of N-hexanoylation to control the thermogelling behavior and prepared a new ocular formulation of HGC for glaucoma therapy. The viscosity of the aqueous formulation sharply and significantly increases at body temperature. The results from cytotoxicity evaluation showed that HGC is non-toxic at up to 1.25wt.%. In vivo experiments demonstrated that HGC is maintained on the preocular surface for a comparatively longer period of time due to its enhanced viscosity at body temperature. As a result, when brimonidine was loaded, the formulation exhibited attractive bioavailability properties as well as more prolonged period of lowered intra-ocular pressure (14h) compared with Alphagan P, the marketed medication for brimonidine treatment. In this manuscript, hexanoyl glycol chitosan (HGC) was synthesized by the N-hexanoylation of glycol chitosan. We have observed that an aqueous solution of HGC exhibited a dramatic increase in viscosity as the temperature increased. The HGC-based formulation showed prolonged retention on the preocular surface and enhanced drug availability and efficacy.
ISSN:1742-7061
1878-7568
DOI:10.1016/j.actbio.2016.05.011